{"id":"https://openalex.org/W2963625979","doi":"https://doi.org/10.1007/s41669-019-0149-9","title":"Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia","display_name":"Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia","publication_year":2019,"publication_date":"2019-06-05","ids":{"openalex":"https://openalex.org/W2963625979","doi":"https://doi.org/10.1007/s41669-019-0149-9","mag":"2963625979","pmid":"https://pubmed.ncbi.nlm.nih.gov/31168754","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7018934"},"language":"en","primary_location":{"id":"doi:10.1007/s41669-019-0149-9","doi":"https://doi.org/10.1007/s41669-019-0149-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s41669-019-0149-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s41669-019-0149-9.pdf","source":{"id":"https://openalex.org/S4210206322","display_name":"PharmacoEconomics - Open","issn_l":"2509-4254","issn":["2509-4254","2509-4262"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics - Open","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s41669-019-0149-9.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053899444","display_name":"H\u00e9l\u00e8ne Paris\u00e9","orcid":"https://orcid.org/0009-0006-4976-904X","observed_orcids":["https://orcid.org/0009-0006-4976-904X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H\u00e9l\u00e8ne Parise","raw_affiliation_strings":["Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061686280","display_name":"Robert Espinosa","orcid":"https://orcid.org/0000-0001-6961-5693","observed_orcids":["https://orcid.org/0000-0001-6961-5693"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Robert Espinosa","raw_affiliation_strings":["Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA. robert.espinosa@medicuseconomics.com","Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA"],"raw_orcid":"https://orcid.org/0000-0001-6961-5693","affiliations":[{"raw_affiliation_string":"Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA. robert.espinosa@medicuseconomics.com","institution_ids":[]},{"raw_affiliation_string":"Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112457032","display_name":"Katherine Dea","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katherine Dea","raw_affiliation_strings":["Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicus Economics LLC, 2 Stonehill Ln, Milton, MA, 02186, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113950684","display_name":"Pablo Anaya","orcid":"https://orcid.org/0000-0003-3088-4946","observed_orcids":["https://orcid.org/0000-0003-3088-4946"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pablo Anaya","raw_affiliation_strings":["IQVIA, Mexico City, CDMX, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IQVIA, Mexico City, CDMX, Mexico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101496493","display_name":"Giovanny Montoya","orcid":"https://orcid.org/0000-0002-4842-3518","observed_orcids":["https://orcid.org/0000-0002-4842-3518"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giovanny Montoya","raw_affiliation_strings":["Astellas Farma Colombia, S.A.S, Bogot\u00e1, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Farma Colombia, S.A.S, Bogot\u00e1, Colombia","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074802928","display_name":"Daniel Ng","orcid":"https://orcid.org/0000-0002-1687-9502","observed_orcids":["https://orcid.org/0000-0002-1687-9502"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Bin Ng","raw_affiliation_strings":["Astellas Pharma Global Development, Inc, Northbrook, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Global Development, Inc, Northbrook, IL, USA","institution_ids":["https://openalex.org/I4210165171"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5061686280"],"corresponding_institution_ids":[],"apc_list":{"value":2200,"currency":"USD","value_usd":2200},"apc_paid":{"value":2200,"currency":"USD","value_usd":2200},"fwci":2.0513,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.86046394,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":96},"biblio":{"volume":"4","issue":"1","first_page":"79","last_page":"90"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.8496000170707703,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.8496000170707703,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.121799997985363,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10418","display_name":"Pelvic floor disorders treatments","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirabegron","display_name":"mirabegron","score":0.9909999966621399},{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.9430000185966492},{"id":"https://openalex.org/keywords/tolterodine-extended-release","display_name":"tolterodine extended release","score":0.9890000224113464},{"id":"https://openalex.org/keywords/antimuscarinic-agents","display_name":"antimuscarinic agents","score":0.953000009059906},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9240000247955322},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8230000138282776},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9520000219345093},{"id":"https://openalex.org/keywords/third-party-payer-perspective","display_name":"third-party payer perspective","score":0.8190000057220459},{"id":"https://openalex.org/keywords/colombia","display_name":"Colombia","score":0.7490000128746033}],"concepts":[{"id":"https://openalex.org/C2778164427","wikidata":"https://www.wikidata.org/wiki/Q3702534","display_name":"Mirabegron","level":4,"score":0.9035253524780273},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.8691509962081909},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.748896062374115},{"id":"https://openalex.org/C2781020410","wikidata":"https://www.wikidata.org/wiki/Q424312","display_name":"Tolterodine","level":4,"score":0.7256017327308655},{"id":"https://openalex.org/C2777844464","wikidata":"https://www.wikidata.org/wiki/Q1060922","display_name":"Oxybutynin","level":4,"score":0.6589260697364807},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6586169004440308},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.4898492991924286},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.37961599230766296},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30346906185150146},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.1007/s41669-019-0149-9","doi":"https://doi.org/10.1007/s41669-019-0149-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s41669-019-0149-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s41669-019-0149-9.pdf","source":{"id":"https://openalex.org/S4210206322","display_name":"PharmacoEconomics - Open","issn_l":"2509-4254","issn":["2509-4254","2509-4262"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics - Open","raw_type":"journal-article"},{"id":"pmid:31168754","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31168754","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics - open","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7018934","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7018934/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacoecon Open","raw_type":"Text"},{"id":"pmh:oai:RePEc:spr:pharmo:v:4:y:2020:i:1:d:10.1007_s41669-019-0149-9","doi":null,"is_oa":false,"landing_page_url":"http://link.springer.com/10.1007/s41669-019-0149-9","pdf_url":null,"source":{"id":"https://openalex.org/S4306401271","display_name":"RePEc: Research Papers in Economics","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I77793887","host_organization_name":"Federal Reserve Bank of St. Louis","host_organization_lineage":["https://openalex.org/I77793887"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s41669-019-0149-9","doi":"https://doi.org/10.1007/s41669-019-0149-9","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s41669-019-0149-9","pdf_url":"https://link.springer.com/content/pdf/10.1007/s41669-019-0149-9.pdf","source":{"id":"https://openalex.org/S4210206322","display_name":"PharmacoEconomics - Open","issn_l":"2509-4254","issn":["2509-4254","2509-4262"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-20","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PharmacoEconomics - Open","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2963625979.pdf","grobid_xml":"https://content.openalex.org/works/W2963625979.grobid-xml"},"referenced_works_count":61,"referenced_works":["https://openalex.org/W1565428119","https://openalex.org/W1602886608","https://openalex.org/W1615359984","https://openalex.org/W1945778360","https://openalex.org/W1967308752","https://openalex.org/W1967322235","https://openalex.org/W1986758727","https://openalex.org/W1987641034","https://openalex.org/W2002743872","https://openalex.org/W2007090935","https://openalex.org/W2007982310","https://openalex.org/W2013191621","https://openalex.org/W2019908863","https://openalex.org/W2027730601","https://openalex.org/W2028475108","https://openalex.org/W2037706235","https://openalex.org/W2044052409","https://openalex.org/W2049325987","https://openalex.org/W2060513754","https://openalex.org/W2062281484","https://openalex.org/W2067449061","https://openalex.org/W2067945145","https://openalex.org/W2069244600","https://openalex.org/W2074581746","https://openalex.org/W2074760879","https://openalex.org/W2082897746","https://openalex.org/W2083379102","https://openalex.org/W2084355008","https://openalex.org/W2093455821","https://openalex.org/W2096360296","https://openalex.org/W2104019772","https://openalex.org/W2105391780","https://openalex.org/W2109034797","https://openalex.org/W2110991424","https://openalex.org/W2115070503","https://openalex.org/W2119629301","https://openalex.org/W2122491820","https://openalex.org/W2127263887","https://openalex.org/W2128473443","https://openalex.org/W2134928141","https://openalex.org/W2139337687","https://openalex.org/W2150712216","https://openalex.org/W2158747623","https://openalex.org/W2161995988","https://openalex.org/W2162173660","https://openalex.org/W2168499550","https://openalex.org/W2241034500","https://openalex.org/W2257575319","https://openalex.org/W2315784927","https://openalex.org/W2317262150","https://openalex.org/W2333249832","https://openalex.org/W2400171190","https://openalex.org/W2466767377","https://openalex.org/W2529284522","https://openalex.org/W2559222418","https://openalex.org/W2754529517","https://openalex.org/W2800521692","https://openalex.org/W2802068944","https://openalex.org/W2981113283","https://openalex.org/W4245187582","https://openalex.org/W7054777211"],"related_works":["https://openalex.org/W2096360296","https://openalex.org/W2540498085","https://openalex.org/W2466767377","https://openalex.org/W2909160308","https://openalex.org/W2809711898","https://openalex.org/W2084274868","https://openalex.org/W2020407610","https://openalex.org/W2995488691","https://openalex.org/W7099956145","https://openalex.org/W4297965543"],"abstract_inverted_index":{"OBJECTIVES:":[0],"The":[1,62],"aim":[2],"of":[3,12,34,55,118,177,196,205,233,248,269],"this":[4],"study":[5],"was":[6,166,226],"to":[7,15,262],"evaluate":[8],"the":[9,32,45,184,194,246,267],"cost":[10,167,227,259],"effectiveness":[11],"mirabegron":[13,102,198,225],"relative":[14],"two":[16],"antimuscarinics,":[17],"oxybutynin":[18,216,237,263],"extended":[19],"release":[20],"(ER)":[21],"and":[22,50,66,76,104,122,128,146,150,210,217,231,238,243,264],"tolterodine":[23,265],"ER,":[24],"in":[25,38,52,159,229,273],"patients":[26,57,85],"with":[27,236],"overactive":[28],"bladder":[29],"(OAB)":[30],"from":[31,99,133,266],"perspective":[33,268],"a":[35,59,100,174,258,270],"third-party":[36,271],"payer":[37,272],"Colombia.":[39,274],"METHODS:":[40],"A":[41],"Markov":[42],"model":[43,63],"simulated":[44],"therapeutic":[46],"management,":[47],"disease":[48],"course,":[49],"complications":[51],"hypothetical":[53],"cohorts":[54],"OAB":[56],"over":[58],"5-year":[60],"period.":[61],"predicted":[64],"costs":[65],"three":[67,182],"outcomes:":[68],"quality-adjusted":[69],"life-years":[70],"(QALYs),":[71],"micturition":[72],"state":[73,78],"improvement":[74,79],"(MSI),":[75],"incontinence":[77],"(ISI).":[80],"In":[81],"each":[82],"1-month":[83],"cycle,":[84],"could":[86],"transition":[87],"between":[88],"different":[89],"health":[90],"states":[91],"reflecting":[92],"symptom":[93],"severity.":[94],"Transition":[95],"probabilities":[96],"were":[97,131,154],"estimated":[98],"published":[101,144],"trial":[103],"mixed":[105],"treatment":[106,112],"comparison.":[107],"Other":[108],"inputs":[109],"such":[110],"as":[111,193,245],"discontinuation":[113],"based":[114],"on":[115],"treatment-specific":[116],"rates":[117],"persistence,":[119],"resource":[120],"use":[121],"costs,":[123],"anticholinergic":[124],"burden,":[125],"comorbidity":[126],"treatment,":[127],"drug":[129],"acquisition":[130],"obtained":[132],"Societ\u00e0":[134],"Italiana":[135],"Scienze":[136],"Mediche,":[137],"Instituto":[138],"de":[139],"Seguros":[140],"Sociales":[141],"Tariff":[142],"Manual,":[143],"literature,":[145],"expert":[147],"opinion.":[148],"Deterministic":[149],"probabilistic":[151],"sensitivity":[152,221],"analyses":[153,222],"conducted.":[155],"Costs":[156],"are":[157],"presented":[158],"2017":[160],"Colombia":[161],"Pesos":[162],"(COP).":[163],"RESULTS:":[164],"Mirabegron":[165,256],"effective":[168,228,260],"for":[169],"all":[170],"outcome":[171],"measures":[172],"at":[173],"willingness-to-pay":[175],"threshold":[176],"124,919,725":[178],"COP,":[179],"which":[180],"is":[181,257],"times":[183],"per":[185],"capita":[186],"gross":[187],"domestic":[188],"product":[189],"(GDP).":[190],"Using":[191,241],"QALYs":[192],"measure":[195,247],"effect,":[197],"had":[199],"an":[200],"incremental":[201],"cost-effectiveness":[202],"ratio":[203],"(ICER)":[204],"85,802,036":[206],"COP/QALY":[207,212],"(26,365":[208],"USD/QALY)":[209,214],"66,360,134":[211],"(20,384":[213],"versus":[215],"tolterodine,":[218,239],"respectively.":[219,240],"Probabilistic":[220],"showed":[223],"that":[224],"99.5%":[230],"100%":[232],"simulations":[234],"compared":[235],"MSI":[242],"ISI":[244],"effects":[249],"yielded":[250],"ICERs":[251],"below":[252],"one":[253],"GDP.":[254],"CONCLUSIONS:":[255],"alternative":[261]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2019-07-30T00:00:00"}